Saturday, 17 October 2026European Markets

SALMONES CAMANCHAC Stock Bullish By 21% In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of SALMONES CAMANCHAC (Oslo Børs All-share Index_GI: SACAM.OL) jumped by a staggering 21.59% in 10 sessions from 37.71 kr to 45.85 kr at 13:41 EST on Monday, after three consecutive sessions in a row of gains. Oslo Børs All-share Index_GI is sliding 0.32% to 1,413.65 kr, after four consecutive sessions in a row of losses.

SALMONES CAMANCHAC's last close was 45.00 kr, 9.84% higher than its 52-week high of 40.97 kr.

About SALMONES CAMANCHAC

Salmones Camanchaca S.A. engages in the salmon farming business in Chile. It offers Atlantic Salmon, Coho Salmon in various formats, such as whole, fillet, portion, block, and other products including, bits and pieces, harasu, and scrape meat. It also exports its products to the United States, Russia, Brazil, Chile, China, Mexico, Korea, Japan, Argentina, and internationally. The company was incorporated in 2009 and is based in Santiago, Chile. Salmones Camanchaca S.A. is a subsidiary of Camanchaca S.A.

Earnings Per Share

As for profitability, SALMONES CAMANCHAC has a trailing twelve months EPS of -3.97 kr.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 25.53%.

Volume

Today's last reported volume for SALMONES CAMANCHAC is 423 which is 97.84% below its average volume of 19672.

Earnings Before Interest, Taxes, Depreciation, and Amortization

SALMONES CAMANCHAC's EBITDA is 134.16.

Sales Growth

SALMONES CAMANCHAC's sales growth for the current quarter is negative 15.7%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 45.6%, now sitting on 381.94M for the twelve trailing months.

More news about SALMONES CAMANCHAC (SACAM.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com